
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals Inc has demonstrated significant growth potential, particularly through an 18% increase in net product sales of Fanapt compared to the year-ago period, with expectations for sustained revenue growth in 2025 driven by the uptake of Fanapt in bipolar disorder and ongoing interest in Ponvory. The company's fourth-quarter 2024 results showed a robust increase in new patient starts, with new-to-brand prescriptions rising by over 160%, indicating strong market demand and potential for future profitability. Vanda's healthy balance sheet, coupled with ambitious long-term revenue goals and strategic new product launches, further supports a positive outlook for the company's financial performance.
Bears say
Vanda Pharmaceuticals Inc faces several significant risks that contribute to a negative outlook on its stock, including slower-than-expected commercial traction for its key products, Fanapt and Ponvory, along with accelerated generic erosion impacting revenue. The company is also facing negative pricing developments, particularly concerning Medicare reimbursement, and potential regulatory setbacks with late-stage pipeline candidates like tradipitant. Additionally, there are concerns regarding the possibility of adverse developments related to mergers and acquisitions, shareholder base destabilization, and medium- to long-term dilution risks, all of which could undermine financial stability and growth projections.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares